Dr. Tahir Latif, MD
Claim this profileUniversity of Cincinnati Cancer Center-UC Medical Center
Studies Lymphoma
Studies B-Cell Lymphoma
11 reported clinical trials
32 drugs studied
Area of expertise
1Lymphoma
CCND1 positive
t(11;14) positive
Stage IV
2B-Cell Lymphoma
Affiliated Hospitals
Clinical Trials Tahir Latif, MD is currently running
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. The study is conducted in 2 consecutive parts that will be enrolled continuously. In Part A of the study, participants with MRD are randomized to one of two treatment arms or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide administered with or without the anti-CD52 monoclonal antibody, ALLO-647. Part A will culminate with the selection of the lymphodepletion regimen to advance to Part B. Part B will evaluate the selected lymphodepletion regimen followed by cema-cel as compared with observation.
Recruiting1 award Phase 25 criteria
IMPT-314
for Non-Hodgkin's Lymphoma
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Recruiting1 award Phase 1 & 2
More about Tahir Latif, MD
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Tahir Latif, MD has experience with
- Rituximab
- Autologous Hematopoietic Stem Cell Transplantation
- Brentuximab Vedotin
- ALLO-647
- ALLO-501A
- Irinotecan
Breakdown of trials Tahir Latif, MD has run
Lymphoma
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Tahir Latif, MD specialize in?
Is Tahir Latif, MD currently recruiting for clinical trials?
Are there any treatments that Tahir Latif, MD has studied deeply?
What is the best way to schedule an appointment with Tahir Latif, MD?
What is the office address of Tahir Latif, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.